© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Srdan Verstovsek, MD, PhD, provides insight on treatment of primary myelofibrosis, including ruxolitinib, and comments on some of the challenges, unmet needs, and future directions in the field.
April 19th 2022
Srdan Verstovsek, MD, PhD, comments on the patient profile and discusses the typical presentation of patients with myelofibrosis (MF).
An overview of clinical criteria and tools that clinicians use for diagnosis of MF.
Srdan Verstovsek, MD, PhD, reviews the use of symptom scoring systems and prognostic models for MF risk stratification and treatment selection.
A focused discussion on the clinical factors that impact patient prognosis, risk assessment, and disease progression.
Srdan Verstovsek, MD, PhD, expands upon frontline treatment options for primary MF, including Janus kinase (JAK) inhibitors.
A comprehensive review of key efficacy data from clinical trials on ruxolitinib, including COMFORT-I and COMFORT-II.
Srdan Verstovsek, MD, PhD, comments on safety data from the ruxolitinib clinical trials in patients with MF.
Srdan Verstovsek, MD, PhD, reviews how treatment with JAK inhibitors improves symptoms, quality of life, and patient outcomes in primary MF.
A discussion of the benefits of clinical trial enrollment for MF.
Srdan Verstovsek, MD, PhD, discusses the risk of transformation to acute myeloid leukemia (AML) and the potential use of bone marrow transplant in patients with MF.